What's in Jee-Young Lee's pipeline?

Jee-Young Lee has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Jee-Young Lee's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jee-young-lee.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Jee-Young Lee — Portfolio Competitive Intelligence Brief

Jee-Young Lee pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
amantadine sulfate	amantadine sulfate	marketed	Antiviral / Dopamine agonist	Influenza A M2 ion channel; dopamine system (mechanism not fully elucidated)	Virology; Neurology

Therapeutic area mix

Virology; Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Jee-Young Lee:

Cite this brief

Drug Landscape (2026). Jee-Young Lee — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jee-young-lee. Accessed 2026-05-15.